Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965
The monocarboxylate transporter 1 (MCT1) is a key element in tumor cell metabolism and inhibition of MCT1 with AZD3965 is undergoing clinical trials. We aimed to investigate nutrient fluxes associated with MCT1 inhibition by AZD3965 to identify possible biomarkers of drug action. We synthesized an &...
Main Authors: | Marta Braga, Maciej Kaliszczak, Laurence Carroll, Zachary T. Schug, Kathrin Heinzmann, Nicoleta Baxan, Adrian Benito, Gabriel N. Valbuena, Stephen Stribbling, Alice Beckley, Gillian Mackay, Francesco Mauri, John Latigo, Chris Barnes, Hector Keun, Eyal Gottlieb, Eric O. Aboagye |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/6/1703 |
Similar Items
-
In Vivo Anticancer Activity of AZD3965: A Systematic Review
by: Ana Silva, et al.
Published: (2021-12-01) -
Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer
by: Ana Silva, et al.
Published: (2023-11-01) -
Exploring monocarboxylate transporter inhibition for cancer treatment
by: Tomas Koltai, et al.
Published: (2024-02-01) -
In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment
by: Zohra Benyahia, et al.
Published: (2021-02-01) -
Combined treatments with AZD5363, AZD8542, curcumin or resveratrol induce death of human glioblastoma cells by suppressing the PI3K/AKT and SHH signaling pathways
by: Rosalinda Mejía-Rodríguez, et al.
Published: (2023-03-01)